knowledge -WSS

knowledge

author：explore 2025-10-01 00:49:23 - browse：6629

Photo illustration of Covid 19 testing swabs on a blue background. — Timothy Stenzel led the FDA's diagnostics division during the Covid-19 pandemic, as the agency scrambled to push through and validate accurate Covid tests. Adobe

Timothy Stenzel, the federal regulator who led the Food and Drug Administration’s diagnostics division during the chaotic time of Covid-19 pandemic, has left the agency. The FDA confirmed Thursday that Stenzel, who led the FDA’s office of in vitro diagnostics, retired at the end of 2023.

During the early days of the pandemic, Stenzel was in the middle of a turf battle between the Centers for Disease Control and Prevention and the FDA over the regulation of Covid tests. At one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development, Politico reported at the time.

It was a hectic time. Testmakers rapidly introduced new Covid-19 screening products with little data, as it was a brand new virus. The pandemic especially laid bare FDA’s inability to control lab-developed tests (LDTs). Many of the Covid-19 PCR tests fell in this category. Early on, using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. But a STAT investigation found that the Department of Health and Human Services told the FDA to stop this measure, despite knowing that many of the tests may have been inaccurate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： People can get long Covid without testing positive for virus: Study

hotspot

WSS

Study: New antibiotic targets gonorrhea as well as last existing drug

PBMs are inflating the cost of generic drugs. They must be reined in

Study: Spinal cord stimulation helps patients with paralysis walk again

Medicare will require more price transparency from hospitals

How the drug

10 million people disenrolled from Medicaid over past six months

hotspot

knowledge

hotspot

Moonlake's readout produced a cash windfall. Risks remain

More doctors should go into startup world

What does generative AI mean for health care? We asked experts

Medicare will require more price transparency from hospitals

Wildfire smoke exposes gaps in outdoor worker protections

Former Pear Therapeutics executives start new VC firm

The cancer drug shortage isn’t new — and neither are the solutions

Roche's accidental data boosts hopes for anti

Cancer drug shortages should be causing more outrage

10 million people disenrolled from Medicaid over past six months

leisure time

Diversify hospital leadership teams to protect BIPOC patient health

How the first Native Hawaiian psychiatrist helped diversify medicine

Former Pear Therapeutics executives start new VC firm

Listen: Vivek Ramaswamy's star turn & leaky drug data

PBMs are inflating the cost of generic drugs. They must be reined in

CDC says it’s too soon to assess risk posed by Covid subvariant

hotspot

hotspot

knowledge

focus